Just a mention of ivermectin. Interesting article though.
Still, experts say the analysis shows that huge amounts of energy have been expended on haphazard efforts, often without a clear strategy to improve the odds that results would actually inform the care of patients. Faced with intense pressure to develop drugs and vaccines at previously unimaginable speed to push back a global pandemic, researchers may have actually slowed down the rate of progress.
For instance, 237,000 patient volunteers were to be enrolled in studies of hydroxychloroquine or chloroquine. That’s 35% of the 685,000 patient volunteers whom researchers hoped would be enrolled in any study. Since patients willing to enter studies are one of the scarcest resources in medicine, this means that other potential treatments, such as ivermectin or favipiravir, were not studied.
That’s “excessive,” said Susan Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation. She noted that vaccines, in contrast, are being developed in a more methodical way — and wished that research on new drugs had been more organized, rather than simply trying whatever was available.
An awful lot of trails, including ivermectin trials, are in the pre-recruiting or recruiting phases, suggesting too few patients. Too bad more research isn't being done in TX/FL/CA.
[-] TrumpLyftAlles | 1 points | Jul 21 2020 17:34:05
Just a mention of ivermectin. Interesting article though.
Still, experts say the analysis shows that huge amounts of energy have been expended on haphazard efforts, often without a clear strategy to improve the odds that results would actually inform the care of patients. Faced with intense pressure to develop drugs and vaccines at previously unimaginable speed to push back a global pandemic, researchers may have actually slowed down the rate of progress.
For instance, 237,000 patient volunteers were to be enrolled in studies of hydroxychloroquine or chloroquine. That’s 35% of the 685,000 patient volunteers whom researchers hoped would be enrolled in any study. Since patients willing to enter studies are one of the scarcest resources in medicine, this means that other potential treatments, such as ivermectin or favipiravir, were not studied.
That’s “excessive,” said Susan Desmond-Hellmann, former CEO of the Bill and Melinda Gates Foundation. She noted that vaccines, in contrast, are being developed in a more methodical way — and wished that research on new drugs had been more organized, rather than simply trying whatever was available.
An awful lot of trails, including ivermectin trials, are in the pre-recruiting or recruiting phases, suggesting too few patients. Too bad more research isn't being done in TX/FL/CA.
permalink